What is Character?
Headquartered in Jersey City, New Jersey, Character Biosciences—formerly known as Clover Therapeutics—is a precision medicine firm dedicated to revolutionizing drug development for complex, polygenic conditions. The company utilizes a sophisticated integration of genomics, clinical data, and AI-driven modeling to pinpoint the molecular drivers of disease progression. Its initial therapeutic focus centers on ophthalmology, specifically targeting age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG). By identifying specific genetic markers, the firm aims to significantly improve the success rates of clinical trials and accelerate the delivery of targeted therapies to patients with high unmet medical needs.
The company's growth trajectory has been marked by a series of strategic financing rounds, beginning with early-stage backing and evolving into the current major enterprise-level funding. This progression reflects the firm's ability to translate complex biological data into actionable therapeutic insights, positioning it as a critical player in the future of personalized healthcare.
How much funding has Character raised?
Character has raised a total of $136.9M across 3 funding rounds:
Other Financing Round
$18M
Private Equity
$8.9M
Series B
$110M
Other Financing Round (2022): $18M with participation from Innovation Endeavors and Section 32
Private Equity (2025): $8.9M, investors not publicly disclosed
Series B (2025): $110M supported by KdT Ventures, Luma Group, aMoon, S32, Innovation Endeavors, Bausch & Lomb, and Catalio Capital Management
Key Investors in Character
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials.
Innovation Endeavors
Innovation Endeavors is an early-stage venture capital firm that invests in visionary founders and transformational technologies, with a strong focus on life sciences and data-driven computation.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing, with a specific focus on breakthrough biomedical technology companies.
What's next for Character?
With the successful closure of this latest financing round, Character Biosciences is well-positioned to scale its AI-driven discovery platform and advance its lead candidates through the clinical pipeline. The strategic capital will likely be deployed to expand the company's data infrastructure and deepen its research into additional polygenic disease areas beyond ophthalmology. As the firm continues to refine its predictive modeling capabilities, it remains focused on establishing long-term partnerships with global healthcare leaders to validate its platform's efficacy. The current funding environment suggests that Character Biosciences is entering a pivotal phase of commercialization and clinical validation, setting the stage for potential future milestones in the precision medicine market.
See full Character company page
